Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
story of the week
Published in Primary Care and
1 other channel

Journal Scan / Research · June 15, 2022

Effect of Tirzepatide vs Insulin Degludec on Glycaemic Control Measured by CGM in Adults With Type 2 Diabetes

The Lancet Diabetes & Endocrinology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Christophe De Block MD, PhD

The Lancet Diabetes & Endocrinology
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
Lancet Diabetes Endocrinol 2022 Apr 22;[EPub Ahead of Print], T Battelino, RM Bergenstal, A Rodríguez, L Fernández Landó, R Bray, Z Tong, K Brown

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated